Skip to main content

Search

Show all results for

Home

Person

Alessandra Musso

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (5)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

alpha-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9)

Bernard Schneider, Elpida Tsika, Liliane Glauser, Alessandra Musso, Guillaume Daniel, Darren Moore, Aris Nikolaos Fiser

Mutations in the ATP13A2 (PARK9) gene cause early-onset, autosomal recessive Parkinson's disease (PD) and Kufor-Rakeb syndrome. ATP13A2 mRNA is spliced into three distinct isoforms encoding a P5-type ATPase involved in regulating heavy metal transport acro ...

Academic Press Inc Elsevier Science2015

Functional interaction of Parkinsons disease-associated LRRK2 with members of the dynamin GTPase superfamily

Liliane Glauser, Elpida Tsika, Klodjan Stafa, Darren Moore, Alessandra Musso, Amy Jones

Mutations in LRRK2 cause autosomal dominant Parkinsons disease (PD). LRRK2 encodes a multi-domain protein containing GTPase and kinase domains, and putative proteinprotein interaction domains. Familial PD mutations alter the GTPase and kinase activity of L ...

Oxford University Press2014

Exploring the pathological interaction between LRRK2 and alpha-synuclein : two key genes implicated in Parkinson's disease

Alessandra Musso

Parkinson’s disease (PD) is the most common age-related neurodegenerative movement disorder that affects 1-2% of the general population over the age of 65 and rising to 4-5% over 80 years of age. It is estimated that 6.3 million people worldwide have Parki ...

EPFL2014